Best responses to treatment with Ibr or Ibr + R in CLL. (A) Responses in patients with CLL treated with Ibr or Ibr + R. CRs, including CRs with incomplete count recovery (CR/Cri), are depicted in green; PRs, including PR/nPRs, are in blue; and PRLs are in pink. Although the CR rate with the addition of rituximab was higher, it did not reach statistical significance. (B) Responses in treatment-naive (TN) and relapsed/refractory (RR) patients with CLL treated with Ibr or with Ibr + R.